Clinical Trial Update: Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravenous immunoglobulin for chronic inflammatory demyelinating polyneuropathy. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Demyelinating Diseases, Paraproteinemias | Phase 2 | Status: COMPLETED